Literature DB >> 7137984

Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria.

J P O'Keefe, K A Troc, K D Thompson.   

Abstract

Susceptibility of clinical isolates of anaerobic bacteria to metronidazole and its two oxidation products, 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole (the "alcohol" metabolite) and 2-methyl-5-nitroimidazole-1-acetic acid (the "acid" metabolite), were determined by the agar dilution technique. Results disclosed that the alcohol metabolite, although less active than metronidazole, inhibited the organisms tested at levels considered susceptible for metronidazole. The acid metabolite was less active, not inhibiting the organisms at levels within the susceptible range. In other studies, mixtures of known concentrations of metronidazole and the metabolites were assayed in a bioassay system used to measure metronidazole levels. These studies showed that the bioassay will measure metronidazole or the alcohol metabolite; the acid metabolite is not measured at levels achieved in clinical specimens. Since the activity of the alcohol metabolite is comparable to that of metronidazole, we feel that microbiological assays can be used for therapeutic monitoring of metronidazole levels in clinical situations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7137984      PMCID: PMC183761          DOI: 10.1128/AAC.22.3.426

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Bioassay of metronidazole with either anaerobic or aerobic incubation.

Authors:  E D Ralph; W M Kirby
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

Review 2.  Drug therapy: metronidazole.

Authors:  J Koch-Weser; P Goldman
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

3.  Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole.

Authors:  H R Ingham; J B Slekon; C M Roxby
Journal:  Br Med J       Date:  1977-10-15

4.  In vitro and in vivo laboratory comparison of cephalothin and desacetylcephalothin.

Authors:  W E Wick
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

Review 5.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

6.  Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects.

Authors:  I Nilsson-Ehle; B Ursing; P Nilsson-Ehle
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

7.  Rapid microbiological assay for chloramphenicol and tetracyclines.

Authors:  T J Louie; F P Tally; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

  7 in total
  14 in total

1.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

2.  Susceptibility of Clostridium difficile to metronidazole, its bioactive metabolites and tinidazole.

Authors:  R Bannatyne; J Jackowski
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 3.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

4.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers.

Authors:  M N Muscará; J Pedrazzoli; E L Miranda; J G Ferraz; E Hofstätter; G Leite; A F Magalhães; S Leonardi; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

5.  Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Authors:  Kelly A Sprandel; Christopher A Schriever; Susan L Pendland; John P Quinn; Mark H Gotfried; Suzanne Hackett; Mary Beth Graham; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 6.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

8.  Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.

Authors:  G W Houghton; M J Dennis; R Gabriel
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

9.  In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

Authors:  S L Pendland; S C Piscitelli; P C Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Single dose prophylaxis with metronidazole in infants during abdominal surgery: a pharmacokinetic study.

Authors:  A Rubenson; A Rosetzsky
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.